Anavex Life Sciences Corp (AVXL)

[nidan7500]

IMO, the breadcrumbs (from FDA and AVXL) lead to smaller trials with stronger evidence from P1/P2. Pre/clinical evidence used to assess certainty based on precision science with a deeper-precise understanding vs AD plaque assessment then backing into a rationale based on autopsies. IMO, A2-73 and Dr. M's assessment of why it works is the best game in town. Predictions for time to FDA release based on previous models are simply irrelevant, IMO. Put away the shotguns boys.

IMO, this FDA delay-time out period was inevitable (new lab capabilities/new S/W capabilities/old trials practice clearly unsuitable any longer & other). Then A2-73 comes along at exactly the right time providing an excellent example/opportunity to reset. There may be others also but nothing bigger than A2-73.